|View printer-friendly version|
|Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings|
During the AAOS Annual Meeting, from
At the ORS Annual Meeting, on
Additionally, three poster presentations on NeoCart will also be presented during the ORS Annual Meeting. These presentations will take place on
The AAOS Annual Meeting brings orthopedic surgeons from around the world to share their research and experience at the Annual Meeting to deliver flagship education. To learn more about the AAOS Annual Meeting, visit www.aaos.org.
The ORS Annual Meeting is a leading forum for presentations of high quality, innovative and transformative research. For more information on the ORS Annual Meeting, visit www.ors.org.
Important factors that could cause actual results to differ materially from those reflected in Histogenics’ forward-looking statements include, among others: the timing and success of Histogenics’ NeoCart Phase 3 clinical trial, including, without limitation, possible delays in generating the data from the clinical trial; the ability to obtain and maintain regulatory approval of NeoCart or any product candidates, the labeling for any approved products; NeoCart’s regulation as a Regenerative Medical Product; the market size and potential patient population in
All written and verbal forward-looking statements attributable to
Contact: Investor Relations Tel: +1 (781) 547-7909 InvestorRelations@histogenics.com